AU Patent

AU2003216726A1 — Supramolecular polymers

Assigned to Arkema France SA · Expires 2003-07-30 · 23y expired

What this patent protects

The invention relates to a supramolecular polymer containing units which are linked by hydrogen bonds, said units being monomers of prepolymers comprising at least one functional group selected from the functional groups (1) and (3) and a second functional group (5) wherein A den…

USPTO Abstract

The invention relates to a supramolecular polymer containing units which are linked by hydrogen bonds, said units being monomers of prepolymers comprising at least one functional group selected from the functional groups (1) and (3) and a second functional group (5) wherein A denotes oxygen, sulphur or NH and X is any unit; the hydrogen bonds in the supramolecular polymer being formed between two identical or different functional groups chosen from the functional groups (1) to (5). The inventive polymers can be used alone, i.e. in the form of a composition which is essentially made from said polymers and, optionally, stabilizers, antioxidants, etc. or in the form of a mixture with other polymers or other products.

Drugs covered by this patent

Patent Metadata

Patent number
AU2003216726A1
Jurisdiction
AU
Classification
Expires
2003-07-30
Drug substance claim
No
Drug product claim
No
Assignee
Arkema France SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.